We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

Guideline and Recommendations 2023 Clinical Practice Guideline The 2023 guideline contains 25 recommendations and 10 good practice statements with a focus on exercise, nutrition, fracture risk assessment, treatment and more […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

Since the COVID-19 lockdown began and even now as things begin to open up across the country, many health professionals have been consulting with their patients on-line or on the […]

A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]

LIVING WELL WITH OSTEOPOROSIS Managing osteoporosis to live a full and active life You Are Not Alone It is common to feel anxious about your health or lifestyle when diagnosed […]

PROVINCIAL DRUG COVERAGE AS OF FEBRUARY 2024 Coverage is under constant review and is subject to change. Access to a generic equivalent is generally reported to be identical to that […]

BISPHOSPHONATES The most common family of drugs used to treat osteoporosis Bisphosphonates are the most common family of drugs used to treat osteoporosis. They are part of the group of […]

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]